New data should come in on safty in the near term.
Great if we come up with the cure however due to the fact that this is a off the shelf product , all we need is a modest improved outcome and it would be a very marketable product as the cost of it would only be a fraction of Car T and as a off the shelf product it would be available were as Car T has a significant delay often to late for the paitent.
Ann: ADVENT-AML Phase 1B clinical trial open to enrolment, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(16.7%) |
Mkt cap ! $11.37M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $9.689K | 2.768M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 75 | 71790139 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 86946524 | 26 |
View Market Depth
| Last trade - 12.54pm 01/08/2025 (20 minute delay) ? |
| CHM (ASX) Chart |